Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
21 Incredibly Interesting Contemplations To Observe Consistently - 25 Advancement Developments in Biotechnology
- 3Italy now recognizes the crime of femicide and punishes it with life in prison
- 4NASA just launched Artemis 2. What happens today could make or break the moon mission
- 5The beauty advent calendar boom is here. Sephora kids are all in.
- You finally got a doctor's appointment. Here's how to get the most out of it
- Day to day Temporary Positions That Compensate Fairly in the US
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- Dependable Savvy Locks to Update Your Home Security
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- Famous Versatile Brands: Your Decision
- European nations criticise Israel’s death penalty plans
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
